Reviewing BioLargo (BLGO) & The Competition
by Kim Johansen · The Markets DailyBioLargo (NASDAQ:BLGO – Get Free Report) is one of 34 publicly-traded companies in the “Chemicals & allied products” industry, but how does it weigh in compared to its peers? We will compare BioLargo to related companies based on the strength of its valuation, risk, analyst recommendations, earnings, institutional ownership, profitability and dividends.
Insider & Institutional Ownership
0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk & Volatility
BioLargo has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.78, meaning that their average stock price is 78% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for BioLargo and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLargo | 0 | 0 | 0 | 0 | N/A |
| BioLargo Competitors | 139 | 1282 | 1596 | 46 | 2.51 |
As a group, “Chemicals & allied products” companies have a potential upside of 6.99%. Given BioLargo’s peers higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its peers.
Valuation & Earnings
This table compares BioLargo and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BioLargo | $12.23 million | -$3.50 million | -8.06 |
| BioLargo Competitors | $6.63 billion | $204.21 million | 65.95 |
BioLargo’s peers have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares BioLargo and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLargo | -16.53% | -58.35% | -32.12% |
| BioLargo Competitors | -568.74% | 5.73% | -0.15% |
Summary
BioLargo peers beat BioLargo on 8 of the 10 factors compared.
BioLargo Company Profile
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.